Edoxaban (Lixiana®, Savaysa®)
|Molecular mass||548,06 Da|
|Bioavailability||approx. 50 %|
|Peak concentration||3 - 4 after drug administration|
|Half-life||9 to 11 hours|
Edoxaban is a drug used to inhibit blood clotting. The mechanism of action is that edoxaban highly selectively inhibits Antithrombin-independent Factor Xa directly. The substance is orally bioavailable. For this reason, edoxaban belongs to the group of direct oral anticoagulants (DOAK). Edoxaban does not inhibit thrombin.
The following indications are indicated: prophylaxis of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation and one or more risk factors, such as congestive heart failure, hypertension, age above 75 years, diabetes mellitus, stroke or transient ischemic attack in the anamnesis; Treatment of deep vein thrombosis and pulmonary embolism and prophylaxis of recurrent deep vein thrombosis and pulmonary embolism.
- Routine monitoring is not necessary
- An anti-factor Xa activity test that is calibrated and controlled with edoxaban is recommended for complications and risk groups.
- He L, Kochan J, Lin M, Vandell A, Brown K, Denpasse F; determination of edoxaban equivalent concentrations in human plasma by an automated anti-factor Xa chromogenic assay. Thromb Res. 155: 121-127, 2017.
- Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Konvacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Zhang G, Zwicker JI, Weitz JI, Büller HR; Hokusai VTE. Cancer Investigations. Edoxaban for the Treatment of Cancer-Associated Venous Thromboebolism. N. Engl J Med. Feb. 15 378(7): 615-624, 2018.
- Stacy Z, Call W, Hartmann A, Peters G; Edoxaban: A comprehensive Review of the Pharmocology and Clinical Data for the Management of Atrial Fibrilliation and Venous Thromboembolism. Cardiol Ther. June 5(1): 1-18, 2018.